CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM…
Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a…
Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a…
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize…
Financing was led by New Enterprise Associates (NEA) and closed with additional new investor Atlas Venture and continued investment by…
Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a…
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…
HeartRisk™ Empowers Employers Who Adopt Cardio Diagnostics’ Solutions to Proactively Combat Cardiovascular Disease in Their Workforce and Mitigate Business RisksCHICAGO--(BUSINESS…
This is the second CPT PLA code the American Medical Association (AMA) granted for the Company’s AI-powered coronary heart disease…
Obtaining a CPT PLA code marks a key milestone in securing reimbursement from federal and private payers for, and expanding…